The COVID-19 pandemic has had a lasting and disproportionate impact on diagnosis rates for various conditions, including depression, asthma, and osteoporosis. According to a study by King's College London, depression saw a 27.7% drop in diagnoses compared to pre-pandemic trends, while asthma, COPD, and osteoporosis diagnoses were also lower than expected. The study, published in the British Medical Journal (BMJ), analyzed anonymized data from over 29 million people in England to assess whether diagnosis rates have recovered post-pandemic. The pandemic's unprecedented impact on healthcare systems worldwide led to abrupt decreases in diagnosis rates for a wide range of diseases. The study also revealed disparities in diagnosis recovery across ethnic and socioeconomic groups. While dementia diagnoses returned to pre-pandemic levels for white individuals and those in less deprived areas, they remained lower than expected among other ethnic groups and in more deprived communities. The study's co-author, Professor Sam Norton, highlighted the striking and puzzling decline in depression diagnoses, noting a partial recovery by late 2021 followed by a marked decline since 2022, particularly among younger adults and those of white or mixed ethnicity. This pattern contradicts other indicators of mental health need, such as increased disability benefit claims for mental health conditions. The study suggests that increasing pressures on the NHS may be causing delays in formal diagnoses, and more people may be accessing mental health support without receiving a formal diagnosis. The team also proposes that pandemic-related disruptions could be behind the fall in diagnoses for asthma, COPD, and osteoporosis, with backlogs in diagnostic testing likely playing a key role. In contrast, chronic kidney disease (CKD) diagnoses have increased by 34.8% compared to expected levels, possibly due to increased testing and awareness following guideline changes and new treatments. The research team utilized the OpenSAFELY platform, a secure and anonymized NHS data platform, to analyze disease trends for 29 million people between April 2016 and November 2024. Dr. Mark Russell, the lead author, emphasized the potential of real-time, anonymized data to transform disease monitoring and inform care delivery, while also highlighting the need for further research to understand the pandemic's long-term impact on diagnosis rates.
